{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:53:28Z","timestamp":1760622808585},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ejim.2011.02.005","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T08:49:04Z","timestamp":1300265344000},"page":"518-521","source":"Crossref","is-referenced-by-count":22,"title":["Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Sergio","family":"Caravita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Beatrice","family":"Secchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Dadone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bencini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2011.02.005_bb0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice: Raynaud's phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2011.02.005_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-857X(03)00019-X","article-title":"Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma","volume":"29","author":"Hummers","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ejim.2011.02.005_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2011.02.005_bb0020","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0755-4982(06)74645-0","article-title":"Bosentan for treatment of active digital ulcers in patients with systemic sclerosis","volume":"35","author":"Launay","year":"2006","journal-title":"Presse M\u00e9d"},{"key":"10.1016\/j.ejim.2011.02.005_bb0025","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis:prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0030","first-page":"2440","article-title":"Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil","volume":"32","author":"Colglazier","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0035","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2011.02.005_bb0040","series-title":"Pulmonary circulation","first-page":"181","article-title":"Pulmonary arterial hypertension associated with connective tissue disease","author":"Fagan","year":"2004"},{"key":"10.1016\/j.ejim.2011.02.005_bb0045","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"American College of Chest Physicians. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2011.02.005_bb0050","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"American Thoracic Society","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2011.02.005_bb0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.semarthrit.2006.10.004","article-title":"Determinants of pulmonary arterial hypertension in scleroderma","volume":"36","author":"Plastiras","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0070","doi-asserted-by":"crossref","first-page":"78S","DOI":"10.1378\/chest.126.1_suppl.78S","article-title":"American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"McLaughlin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2011.02.005_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2011.02.005_bb0080","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2011.02.005_bb0085","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0095","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2011.02.005_bb0100","first-page":"722","article-title":"Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group","volume":"25","author":"Air\u00f2","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00296-006-0222-4","article-title":"Does cyclically Iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results","volume":"27","author":"Caramaschi","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ejim.2011.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/rheumatology\/35.11.1187","article-title":"Intermittent Iloprost infusion therapy of pulmonary hypertension in scleroderma \u2014 a pilot study","volume":"35","author":"Bartosik","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0115","doi-asserted-by":"crossref","unstructured":"Task force on the diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004;25:2243\u20132278.","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"10.1016\/j.ejim.2011.02.005_bb0120","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.126.4.1313","article-title":"New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure","volume":"126","author":"Chemla","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2011.02.005_bb0125","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/art.21131","article-title":"The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study)","volume":"52","author":"Wigley","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1183\/09031936.02.05542002","article-title":"The new clinical trials on pharmacological treatment in pulmonary arterial hypertension","volume":"20","author":"Galie","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2011.02.005_bb0135","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma associated pulmonary arterial hypertension","volume":"12","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2011.02.005_bb0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.02.005_bb0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10067-007-0828-2","article-title":"N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension","volume":"27","author":"Dimitroulas","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.02.005_bb0150","doi-asserted-by":"crossref","first-page":"219(S)","DOI":"10.1378\/chest.128.4_MeetingAbstracts.219S-a","article-title":"Brain natriuretic peptide levels correlate with six minute walk distance and World Health Oraganization Functional Classification in patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"128","author":"Hearth","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2011.02.005_bb0155","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620511000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620511000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T08:24:31Z","timestamp":1560068671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620511000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0953620511000367"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2011.02.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}